Binghe Xu
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Chinese Academy of Medical Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
53
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
649
PubMed author-name match
Trials
Studies that name Binghe Xu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:54 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07664150 · CW-301 FIH Study of CAN016Canwell Biotech Limited · recruiting · Patients With Advanced Solid Tumors · principal investigator
- Ph1/Ph2NCT07208149 · A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)Shenzhen Majory Biotechnology Co., Ltd. · recruiting · Triple-Negative Breast Cancer (TNBC) · principal investigator
- Early Ph1NCT07182435 · Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid TumorsCancer Hospital Chinese Academy of Medical Science, Shenzhen Center · not yet recruiting · Solid Tumor Malignancies · principal investigator
- Ph3NCT06998108 · Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine TherapyBeBetter Med Inc · recruiting · HR+/HER2- Locally Advanced, Metastatic Breast Cancer · principal investigator
- Ph3NCT06954961 · A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerInventisBio Co., Ltd · recruiting · Breast Cancer · principal investigator
- Ph2NCT06810804 · A Phase IIa Study to Evaluate NBQ72SNantong Bencao Quadriga Medical Technology Co. Ltd. · recruiting · Breast Cancer · principal investigator
- Ph1NCT06609187 · A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Breast Cancer, Solid Tumor · principal investigator
- Ph3NCT06343948 · A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)Sichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · HR+HER2- Breast Cancer · principal investigator
- Ph4NCT06245824 · Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer TrialCancer Institute and Hospital, Chinese Academy of Medical Sciences · not yet recruiting · Breast Cancer · principal investigator
- N/ANCT06156761 · Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast CancerCancer Institute and Hospital, Chinese Academy of Medical Sciences · unknown · Breast Cancer · principal investigator
- Ph3NCT05755048 · FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerShanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · unknown · Breast Cancer · principal investigator
- Ph2NCT05749016 · Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast CancerCancer Institute and Hospital, Chinese Academy of Medical Sciences · unknown · Locally Advanced Breast Cancer, Chemotherapy Effect · study director
- Ph2NCT05747326 · Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast CancerCancer Institute and Hospital, Chinese Academy of Medical Sciences · unknown · Breast Cancer · study director
- Ph1/Ph2NCT05747313 · Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast CancerCancer Institute and Hospital, Chinese Academy of Medical Sciences · unknown · Breast Cancer, Chemotherapy Effect · study director
- Ph1/Ph2NCT05700084 · Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid TumorsBeijing Biostar Pharmaceuticals Co., Ltd. · active not recruiting · Advanced Solid Tumor · principal investigator
- Ph3NCT05439499 · This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Ahon Pharmaceutical Co., Ltd. · unknown · Advanced Breast Cancer, Female Breast Cancer · principal investigator
- Ph1NCT05341570 · A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668Betta Pharmaceuticals Co., Ltd. · unknown · Advanced Solid Tumor · principal investigator
- Ph4NCT05291910 · Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast CancerChinese Academy of Medical Sciences · unknown · Breast Cancer · principal investigator
- Early Ph1NCT05245058 · SPH5030 Tablets in Subjects With Advanced Her2-positive Solid TumorsShanghai Pharmaceuticals Holding Co., Ltd · recruiting · HER2-positive Advanced Solid Tumors · principal investigator
- Ph3NCT05077449 · A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast CancerXuanzhu Biopharmaceutical Co., Ltd. · active not recruiting · Advanced Breast Cancer · principal investigator
- Ph3NCT05054751 · GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerGenor Biopharma Co., Ltd. · completed · Locally Advanced or Metastatic Breast Cancer · principal investigator
- Ph1NCT04433494 · A Study of TY-302 in Patients With Advanced Solid TumorsTYK Medicines, Inc · unknown · Breast Cancer, Solid Tumor · principal investigator
- Ph3NCT04400695 · A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2RemeGen Co., Ltd. · recruiting · Breast Cancer · principal investigator
- N/ANCT04289974 · Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast CancerChinese Academy of Medical Sciences · unknown · Breast Cancer · principal investigator
- Ph1NCT03944499 · Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · completed · Solid Tumor, Breast Cancer · principal investigator
- Ph2NCT03923166 · Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast CancerChinese Academy of Medical Sciences · unknown · Breast Cancer · principal investigator
- Ph2NCT03923179 · Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast CancerChinese Academy of Medical Sciences · unknown · Breast Cancer · principal investigator
- Ph2NCT03775928 · Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast CancerCancer Institute and Hospital, Chinese Academy of Medical Sciences · unknown · Triple-negative Breast Cancer · principal investigator
- Ph2NCT03735082 · Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast CancerChinese Academy of Medical Sciences · unknown · Breast Cancer · principal investigator
- Ph1NCT03658070 · A Study of XY0206 in Subjects With Advanced or Metastatic Solid TumoursShijiazhuang Yiling Pharmaceutical Co. Ltd · unknown · Advanced or Metastatic Solid Tumours · principal investigator
- Ph1NCT03508011 · A Study of IMP4297 in Patients With Advanced Solid TumorsImpact Therapeutics, Inc. · completed · Advanced Solid Tumours, Breast Cancer, Ovarian Cancer · principal investigator
- Ph2NCT03251768 · Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer PatientsTianjin SinoBiotech Ltd. · completed · Chemotherapy-induced Neutropenia · principal investigator
- Ph1NCT03246009 · Fusion Protein rHSA/GCSFclinical Study on Breast Cancer PatientsTianjin SinoBiotech Ltd. · completed · Chemotherapy-induced Neutropenia, Cancer, Breast · principal investigator
- N/ANCT03047889 · A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced BreastChinese Academy of Medical Sciences · unknown · Advanced Breast Cancer · principal investigator
- N/ANCT03039062 · Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by ChemotherapyChinese Academy of Medical Sciences · unknown · Chemotherapeutic Toxicity, Malignant Tumor, Liver Injury · principal investigator
- Ph2NCT02947061 · S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast CancerChinese Academy of Medical Sciences · unknown · Breast Cancer Recurrent · principal investigator
- Ph1NCT02881138 · A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid TumorsRemeGen Co., Ltd. · completed · Solid Tumors · principal investigator
- Ph2NCT02829008 · Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer PatientsChinese Academy of Medical Sciences · unknown · Metastatic Breast Cancer · principal investigator
- Ph3NCT02595138 · Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast CancerChinese Academy of Medical Sciences · unknown · Triple Negative Breast Cancer · principal investigator
- Ph1NCT02430311 · The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.AstraZeneca · completed · Advanced Solid Tumours · principal investigator
- Ph3NCT02319187 · Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 TrialChinese Academy of Medical Sciences · unknown · Esophageal Neoplasms · study chair
- Ph2NCT02041338 · Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast CancerChinese Academy of Medical Sciences · unknown · Breast Cancer, Neoadjuvant Chemotherapy · principal investigator
- Ph3NCT01953003 · Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerPierre Fabre Medicament · completed · Malignant Neoplasm of Breast · study chair
- Ph2NCT01939054 · Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer PatientsChinese Academy of Medical Sciences · unknown · Breast Cancer · principal investigator
- Ph2NCT01928680 · Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast CancerChinese Academy of Medical Sciences · unknown · Metastatic Breast Cancer · principal investigator
- Ph3NCT01917279 · Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBCBinghe Xu · unknown · Breast Neoplasms, Neoplasms by Site, Neoplasm Metastasis · principal investigator
- Ph2NCT01492556 · Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast CancerChinese Academy of Medical Sciences · unknown · Breast Cancer · principal investigator
- Ph2NCT01492543 · Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast CancerChinese Academy of Medical Sciences · unknown · Breast Cancer · principal investigator
- N/ANCT01425294 · Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg TreatmentAstraZeneca · terminated · Breast Cancer · principal investigator
- Ph1NCT01278810 · Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer PatientsChinese Academy of Medical Sciences · unknown · Metastatic Breast Cancer · principal investigator
- Ph4NCT01143974 · Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast CancerChinese Academy of Medical Sciences · completed · Locally Advanced Malignant Neoplasm · study chair
- Ph3NCT01134523 · Regimens Comparison for Breast Cancers of Positive Lymph NodesChinese Academy of Medical Sciences · unknown · Breast Cancer · principal investigator
- Ph3NCT01126138 · Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)Chinese Academy of Medical Sciences · unknown · Carcinoma, Invasive Ductal, Breast · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:54 UTC. The ranking covers the 200 most relevant of 649 PubMed records, and a shared surname and initials can bring in a namesake. All 649 on PubMed
- 2,672 citationsRCR 86.7
- 2,392 citationsRCR 180.8
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.N Engl J Med · 20221,024 citationsRCR 73.8
- 643 citationsRCR 32.9
- 619 citationsRCR 21.9
- 606 citationsRCR 55.2
- Calorie Restriction with or without Time-Restricted Eating in Weight Loss.N Engl J Med · 2022412 citationsRCR 33.5
- 386 citationsRCR 24.6
- Ribociclib plus Endocrine Therapy in Early Breast Cancer.N Engl J Med · 2024377 citationsRCR 46.5
- 358 citationsRCR 18.5